Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 13,085 shares, a decrease of 41.5% from the August 15th total of 22,385 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 18,209 shares, the days-to-cover ratio is presently 0.7 days.
Spectral Diagnostics Stock Performance
Shares of OTCMKTS EDTXF opened at $0.90 on Friday. The company’s fifty day moving average is $0.96 and its two-hundred day moving average is $0.98. The firm has a market capitalization of $263.68 million, a P/E ratio of -8.97 and a beta of 0.16. Spectral Diagnostics has a one year low of $0.81 and a one year high of $1.15.
Spectral Diagnostics Company Profile
Spectral Diagnostics, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.
Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Further Reading
- Five stocks we like better than Spectral Diagnostics
- Intel’s Ohio Lifeline? Why the SK Hynix Talks Matter
- Generac Plugs into Amazon for an $8B AI-Powered Deal
- Laser Focus: 2 Optical Stocks Lighting Up AI
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
